Last reviewed · How we verify

NCT05833373: VAST-AF

Vagal Nerve Stimulation for the Treatment of Persistent AF

Status unknown NA Last updated 7 November 2023
What this trial tests

NA trial testing Vagal stimulation with the device tVNS from tVNS Technologies GmbH in Atrial Fibrillation in 120 participants. Status unknown.

Timeline
6 November 2023
Primary endpoint
30 November 2025
20 December 2025

Quick facts

Lead sponsorKrankenhaus Hetzelstift
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment120
Start date6 November 2023
Primary completion30 November 2025
Estimated completion20 December 2025
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Krankenhaus Hetzelstift

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to answer the question whether a transcutaneous stimulation of a certain nerve (Nervus vagus) with a dedicated device reduces the recurrence of the heart rhythm disorder atrial fibrillation. Participants will receive a dedicated nerval stimulation device and will treat themselves on a daily basis for at least an hour per day. Treatment will last for 3 months. Researchers will compare this group with a similar group that uses an ineffective device. Both researcher and patients will be blinded so they do not know which device they will be using.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05833373.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing